2015年3月20日訊 /生物谷BIOON/--據統計，美國醫藥市場份額2014年是3950億美元。GlobalData研究和諮詢公司對美國醫藥市場非常看好，預估5年後，也就是2020年，這個數字將會攀升到5480億美元。
GlobalData的市場分析報告顯示，美國醫藥市場將以年均5.6%的速度增長，驅動其快速增長的因素有哪些呢？歸結如下：醫療保健支出越來越多、人口結構老齡化、慢性病比如糖尿病和肥胖的流行、醫療支出報銷更便捷以及2010年頒布的《患者保護和大眾醫療法》（PPACA）。總結為兩點：日趨完善的醫療保障體系和高效可信賴的FDA。
GlobalData醫療行業動態研究部長Joshua Owide說：「《患者保護和大眾醫療法》和其附件《醫療和教育糾紛調解條例》對美國市民的影響是長久而深遠的，對製藥工業同樣如此。PPACA的頒布意味著醫療保險普及面更廣，越來越多的人新參保或者更改保險方案爭取到了更多補貼。2013年處方藥市場只有2620億美元，2014年增加到了2759億美元。據統計，大約有3200萬市民是新參保的，這就會在10年之間產生至少1150億美元的醫療消費。」
另外，FDA「高效透明、結構化的監管體系」也促進了新藥的快速審批和質量保證，這也是醫藥市場如此繁榮的原因之一。FDA採取了一系列有利於醫藥製造商的舉措。FDA設立的「綠色通道」和「重大突破專門通道」加速了新藥的審批，也讓一些突破性藥物更快上市。2014年，FDA審批了41種新藥，其中有17種是治療罕見病的。同時，美國完善的專利體系也推動了醫藥製造商向研究型企業的轉變，這也加速了新藥的開發。（生物谷Bioon.com）
英文原文：US pharma market to reach $550bn by 2020
Health reforms and the new FDA initiatives among the factors that will help it grow
The US pharmaceutical market is forecast to jump in value from $395bn in 2014 to $548bn by the end of the decade， according to research and consulting firm GlobalData.
The company's latest report finds that this is a Compound Annual Growth Rate (CAGR) of 5.6%， and will be driven by a number of factors.
These include increased healthcare expenditure， an ageing population， the rising prevalence of chronic lifestyle diseases such as diabetes and obesity， universal and easy access to reimbursement for pharmaceutical product costs， and the 2010 Patient Protection and Affordable Care Act (PPACA).
Joshua Owide， GlobalData's director of healthcare industry dynamics， explained that the PPACA and its amendment， the Health Care and Education Reconciliation Act， continue to have a 「substantial impact」 on US citizens， and the country's pharmaceutical industry.
Owide said： 「As the PPACA mandates health insurance coverage for all Americans， the US has witnessed increasing use of prescription drugs among individuals who are newly insured or have shifted to insurance plans that offer premium and cost-sharing subsidies. In 2014， spending on prescription drugs amounted to an estimated $275.9bn， compared with $262.3bn in 2013.
「Around 20 provisions of the healthcare legislation are expected to have a direct or indirect impact on the volume of drug and biologic sales. As many as 32 million formerly uninsured citizens could enter the patient pool， resulting in new business worth $115bn over a period of 10 years.」
GlobalData's report also notes that the FDA's 「transparent， well-structured and competent regulatory system」 that facilitates the approval of pharmaceutical products is also consequently bolstering market growth.
Owide continued： 「New initiatives undertaken by the FDA to strengthen the review and approval process will be advantageous to the industry. Its strong patent system attracts research-based pharmaceutical companies and positively influences growth.
「In 2014， 41 novel drugs were approved by the FDA， 17 of which were for the treatment of rare diseases. Schemes such as the FDA's 'Fast Track Development Program' and 'Breakthrough Designation' accelerate the approval of novel drugs and add value to the market by meeting demand more quickly.」